|
US5120722A
(en)
|
1984-02-08 |
1992-06-09 |
Hoffmann-La Roche Inc. |
Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
|
|
US4857518A
(en)
|
1984-10-04 |
1989-08-15 |
Wisconsin Alumni Research Foundation |
Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
|
|
US4717721A
(en)
|
1985-05-30 |
1988-01-05 |
Howard W. Bremer |
Sidechain homo-vitamin D compounds with preferential anti-cancer activity
|
|
JPH07100685B2
(ja)
|
1985-08-02 |
1995-11-01 |
レオ・ファ−マシュ−ティカル・プロダクツ・リミテッド・エイ／エス（レ−ベンス・ケミスケ・ファブリック・プロデュクチオンスアクチ−セルスカブ） |
新規ビタミンｄ類似体
|
|
US5145846A
(en)
|
1988-01-20 |
1992-09-08 |
Hoffmann-La Roche Inc. |
Vitamin D3 analogs
|
|
US4851401A
(en)
|
1988-07-14 |
1989-07-25 |
Wisconsin Alumni Research Foundation |
Novel cyclopentano-vitamin D analogs
|
|
CA1333616C
(en)
|
1989-03-09 |
1994-12-20 |
Hector F. Deluca |
19-nor-vitamin d compounds
|
|
GB8915770D0
(en)
|
1989-07-10 |
1989-08-31 |
Leo Pharm Prod Ltd |
Chemical compounds
|
|
US4966898A
(en)
|
1989-08-15 |
1990-10-30 |
Merrell Dow Pharmaceuticals Inc. |
4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
|
|
DE4021433A1
(de)
|
1990-07-04 |
1992-01-09 |
Schering Ag |
Antiandrogene mit steroid(3,2-c)pyrazol-struktur
|
|
DE4101953A1
(de)
|
1991-01-19 |
1992-07-23 |
Schering Ag |
23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
|
|
DE4141746A1
(de)
|
1991-12-13 |
1993-06-17 |
Schering Ag |
20-methyl-substituierte vitamin d-derivate
|
|
US5604213A
(en)
|
1992-03-31 |
1997-02-18 |
British Technology Group Limited |
17-substituted steroids useful in cancer treatment
|
|
WO1993020097A1
(en)
|
1992-03-31 |
1993-10-14 |
British Technology Group Ltd. |
17-substituted steroids useful in cancer treatment
|
|
US5547947A
(en)
|
1993-03-11 |
1996-08-20 |
Hoffmann-La Roche Inc. |
Methods of treatment
|
|
ES2127413T3
(es)
|
1993-09-30 |
1999-04-16 |
Btg Int Ltd |
Sintesis de esteroides 17-(3-piridilo).
|
|
US5688977A
(en)
|
1996-02-29 |
1997-11-18 |
Napro Biotherapeutics, Inc. |
Method for docetaxel synthesis
|
|
ATE196844T1
(de)
|
1996-05-22 |
2000-10-15 |
Protarga Inc |
Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
|
|
US5919815A
(en)
|
1996-05-22 |
1999-07-06 |
Neuromedica, Inc. |
Taxane compounds and compositions
|
|
US5795909A
(en)
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
|
GB9622590D0
(en)
|
1996-10-30 |
1997-01-08 |
Leo Pharm Prod Ltd |
Chemical compounds
|
|
US20020128240A1
(en)
|
1996-12-30 |
2002-09-12 |
Bone Care International, Inc. |
Treatment of hyperproliferative diseases using active vitamin D analogues
|
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
|
US20050233958A1
(en)
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
|
US6087350A
(en)
|
1997-08-29 |
2000-07-11 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
|
|
EP2340840B1
(en)
|
1998-03-27 |
2012-08-29 |
Oregon Health Sciences University |
Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases
|
|
US20030083231A1
(en)
|
1998-11-24 |
2003-05-01 |
Ahlem Clarence N. |
Blood cell deficiency treatment method
|
|
JP2002533404A
(ja)
|
1998-12-23 |
2002-10-08 |
ジー・ディー・サール・アンド・カンパニー |
新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法
|
|
DK1276482T3
(da)
|
2000-03-02 |
2008-05-26 |
Univ Pittsburgh |
Kombinationskemoterapi
|
|
EP1284272A4
(en)
|
2000-04-24 |
2003-09-10 |
Kyowa Hakko Kogyo Kk |
ESTRA-1,3,5 (10) -TRIENE DERIVATIVES
|
|
ATE322266T1
(de)
|
2000-05-15 |
2006-04-15 |
Celgene Corp |
Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
|
|
EP1676577A1
(en)
|
2000-05-15 |
2006-07-05 |
Celgene Corporation |
Compositions for the treatment of cancer comprising a topoisomerase inhibitor and thalidomide
|
|
CN1981873A
(zh)
|
2000-06-09 |
2007-06-20 |
莱古伦公司 |
制备微胶粒的方法和所述微胶粒的用途
|
|
AU2000260772A1
(en)
|
2000-07-05 |
2002-01-14 |
Bryan Muehlberger |
Systems and methods of facilitating electronic payment transactions
|
|
AU2002226877B2
(en)
|
2000-10-17 |
2006-01-12 |
Merck & Co., Inc. |
Orally active salts with tyrosine kinase activity
|
|
US6750213B2
(en)
|
2000-10-19 |
2004-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
DE10061137B4
(de)
|
2000-12-07 |
2016-10-06 |
Takeda Gmbh |
Neue pharmazeutische Zubereitung
|
|
US20040092583A1
(en)
|
2001-01-02 |
2004-05-13 |
Elizabeth Shanahan-Prendergast |
Treatment for inhibiting neoplastic lesions
|
|
JP4401076B2
(ja)
|
2001-04-18 |
2010-01-20 |
ユーロ−セルティーク エス．エイ． |
ベンズイミダゾロン化合物
|
|
EP2033644A1
(en)
|
2001-04-18 |
2009-03-11 |
Euro-Celtique S.A. |
Spiroindene and spiroindane compounds
|
|
YU82403A
(sh)
|
2001-04-18 |
2006-08-17 |
Euroceltique S.A. |
Jedinjenja spiropirazola
|
|
CZ20032850A3
(cs)
|
2001-04-18 |
2004-02-18 |
Euro-Celtique, S. A. |
Analogy nociceptinu
|
|
WO2002091993A2
(en)
|
2001-05-10 |
2002-11-21 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
WO2002102783A1
(en)
|
2001-06-19 |
2002-12-27 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6740641B2
(en)
|
2001-07-27 |
2004-05-25 |
Euro-Celtique, S.A. |
Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
|
|
US7186723B2
(en)
|
2001-08-30 |
2007-03-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
CA2459311C
(en)
|
2001-09-06 |
2010-08-03 |
Schering Corporation |
17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
|
|
WO2003037252A2
(en)
|
2001-10-30 |
2003-05-08 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
WO2003039460A2
(en)
|
2001-11-07 |
2003-05-15 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
|
DE60222302T2
(de)
|
2001-12-06 |
2008-05-29 |
Merck & Co., Inc. |
Inhibitoren von mitotischem kinesin
|
|
ES2345044T3
(es)
|
2002-02-01 |
2010-09-14 |
Euro-Celtique S.A. |
2-piperazin-piridinas utiles para tratar el dolor.
|
|
EP1336602A1
(en)
|
2002-02-13 |
2003-08-20 |
Giovanni Scaramuzzino |
Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
|
|
US6974818B2
(en)
|
2002-03-01 |
2005-12-13 |
Euro-Celtique S.A. |
1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
|
|
AU2003211877A1
(en)
|
2002-03-11 |
2003-09-22 |
Takeda Chemical Industries, Ltd. |
Remedies for sex hormone-dependent disease
|
|
CA2481241C
(en)
|
2002-04-08 |
2010-07-27 |
Merck & Co., Inc. |
Fused quinoxaline derivatives as inhibitors of akt activity
|
|
EP1927858B1
(en)
|
2002-04-29 |
2013-01-09 |
Euro-Celtique S.A. |
Conformationally constrained peptides that bind the ORL-1 receptor
|
|
AU2003241326B2
(en)
|
2002-05-02 |
2008-05-01 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
ATE356804T1
(de)
|
2002-06-14 |
2007-04-15 |
Merck & Co Inc |
Inhibitoren von mitotischem kinesin
|
|
DE60318875T2
(de)
|
2002-06-28 |
2009-01-15 |
Euro-Celtique S.A. |
Therapeutische piperazin-derivate für die behandlung von schmerzen
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
|
EP1534336A4
(en)
|
2002-08-15 |
2005-12-14 |
Human Genome Sciences Inc |
ANTIBODIES IMMUNOSPECIFICALLY FIXING TO TRAIL RECEPTORS
|
|
CA2496867A1
(en)
|
2002-08-28 |
2004-03-11 |
Hollis-Eden Pharmaceuticals, Inc. |
Therapeutic treatment methods
|
|
US20050101581A1
(en)
|
2002-08-28 |
2005-05-12 |
Reading Christopher L. |
Therapeutic treatment methods 2
|
|
US7157462B2
(en)
|
2002-09-24 |
2007-01-02 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
CN100528167C
(zh)
|
2002-10-23 |
2009-08-19 |
潘塔希生物科学股份有限公司 |
用于治疗癌症的包含雌四醇衍生物的药物组合物
|
|
WO2004041164A2
(en)
|
2002-10-30 |
2004-05-21 |
Merck & Co., Inc. |
Kinase inhibitors
|
|
US7202259B2
(en)
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
ATE409065T1
(de)
|
2002-12-17 |
2008-10-15 |
Schering Corp |
Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
|
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
|
EP1583539A2
(en)
|
2003-01-13 |
2005-10-12 |
Cedars-Sinai Medical Center |
Paricalcitol as a chemotherapeutic agent
|
|
TWI330079B
(en)
|
2003-01-15 |
2010-09-11 |
Synta Pharmaceuticals Corp |
Treatment for cancers
|
|
EP1633316A4
(en)
|
2003-05-06 |
2008-04-02 |
Human Genome Sciences Inc |
ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
|
|
US20050020546A1
(en)
|
2003-06-11 |
2005-01-27 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
|
MY142655A
(en)
|
2003-06-12 |
2010-12-15 |
Euro Celtique Sa |
Therapeutic agents useful for treating pain
|
|
ES2327684T3
(es)
|
2003-07-24 |
2009-11-02 |
Euro-Celtique S.A. |
Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor.
|
|
PL1867644T3
(pl)
|
2003-07-24 |
2009-10-30 |
Euro Celtique Sa |
Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
|
|
US7071333B2
(en)
|
2003-07-30 |
2006-07-04 |
Bristol-Myers Squibb Company |
Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
|
|
SI1942106T1
(sl)
|
2003-08-01 |
2012-01-31 |
Euro Celtique Sa |
Terapevtska sredstva, uporabna za zdravljenje bolečine
|
|
EP1660436A4
(en)
|
2003-08-27 |
2006-11-22 |
Merck Frosst Canada Ltd |
cathepsin inhibitors
|
|
PL1664041T3
(pl)
|
2003-09-22 |
2008-12-31 |
Euro Celtique Sa |
Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
|
|
PT1664016E
(pt)
|
2003-09-22 |
2008-12-29 |
Euro Celtique Sa |
Agentes terapêuticos úteis para tratamento da dor
|
|
AU2004283479A1
(en)
|
2003-10-17 |
2005-05-06 |
4 Aza Bioscience Nv |
Heterocycle-substituted pteridine derivatives and their use in therapy
|
|
WO2005107801A2
(en)
|
2004-04-29 |
2005-11-17 |
The Regents Of The University Of Colorado |
Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies
|
|
US20060003950A1
(en)
|
2004-06-30 |
2006-01-05 |
Bone Care International, Inc. |
Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
|
|
US7094775B2
(en)
|
2004-06-30 |
2006-08-22 |
Bone Care International, Llc |
Method of treating breast cancer using a combination of vitamin D analogues and other agents
|
|
US20060030608A1
(en)
|
2004-08-04 |
2006-02-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Anti aromatase compounds pharmaceutical compositions and uses thereof
|
|
GB0418900D0
(en)
|
2004-08-24 |
2004-09-29 |
Btg Int Ltd |
Novel salt forms
|
|
CA2579732C
(en)
|
2004-09-10 |
2014-08-12 |
Nitec Pharma Ag |
Tablets with site time-controlled gastrointestinal release of active ingredient
|
|
AR051597A1
(es)
|
2004-11-01 |
2007-01-24 |
Merck & Co Inc |
Moduladores de los receptores de estrogeno
|
|
EP1674479A1
(en)
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulation of Fc Gamma receptors for optimizing immunotherapy
|
|
WO2006081152A2
(en)
|
2005-01-24 |
2006-08-03 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
CA2606226A1
(en)
|
2005-04-27 |
2006-11-02 |
University Of Florida Research Foundation, Inc. |
Materials and methods for enhanced degradation of mutant proteins associated with human disease
|
|
JP2008539238A
(ja)
|
2005-04-28 |
2008-11-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド |
治療用二機能性化合物
|
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
|
WO2007014327A2
(en)
|
2005-07-27 |
2007-02-01 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
|
JP4611441B2
(ja)
|
2006-04-03 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
|
|
US20100016409A1
(en)
|
2006-06-02 |
2010-01-21 |
Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services |
Rna Nanoparticles and Nanotubes
|
|
US7884107B2
(en)
|
2006-06-30 |
2011-02-08 |
Merck |
Substituted piperidines that increase P53 activity and the uses thereof
|
|
CA2656393A1
(en)
|
2006-06-30 |
2008-01-10 |
Schering Corporation |
Method of using substituted piperidines that increase p53 activity
|
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
|
US20080051375A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
|
|
NZ597830A
(en)
|
2006-08-25 |
2013-02-22 |
Cougar Biotechnology Inc |
Methods and compositions for treating cancer comprising abiraterone acetate and prednisone
|
|
EP2081964A4
(en)
|
2006-10-12 |
2012-07-11 |
Univ Johns Hopkins |
ALGINATE AND ALGINATLYASE COMPOSITIONS AND USE METHOD
|
|
EP2081565A2
(en)
|
2006-10-13 |
2009-07-29 |
Reliance Life Sciences Pvt., Ltd. |
Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
|
|
RS51780B
(sr)
|
2007-01-10 |
2011-12-31 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. |
Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
|
|
EP2491923A3
(en)
|
2007-02-15 |
2012-12-26 |
Novartis AG |
Combinations of therapeutic agents for treating cancer
|
|
WO2008109740A2
(en)
|
2007-03-06 |
2008-09-12 |
Colby Pharmaceutical Company |
Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
|
|
US20090124587A1
(en)
|
2007-07-12 |
2009-05-14 |
Auerbach Alan H |
METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
|
NZ586675A
(en)
|
2008-01-08 |
2012-04-27 |
Merck Sharp & Dohme |
Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
|
|
PL2276767T3
(pl)
|
2008-03-31 |
2014-09-30 |
Genentech Inc |
Związki benzopiranowe i benzoksepinowe będące inhibitorami pi3k oraz metody ich stosowania
|
|
WO2009137717A1
(en)
|
2008-05-07 |
2009-11-12 |
Cardioxyl Pharmaceuticals Inc. |
Novel nitroso compounds as nitroxyl donors and methods of use thereof
|
|
WO2012009475A1
(en)
|
2010-07-14 |
2012-01-19 |
Oregon Health & Science University |
Methods of treating cancer with inhibition of lysine-specific demethylase 1
|
|
US9314473B2
(en)
|
2011-02-03 |
2016-04-19 |
Pop Test Oncology Limited Liability Company |
System and method for diagnosis and treatment
|
|
US8658128B2
(en)
|
2011-02-03 |
2014-02-25 |
Pop Test Cortisol Llc |
System and method for diagnosis and treatment
|
|
UA117663C2
(uk)
*
|
2012-09-26 |
2018-09-10 |
Арагон Фармасьютікалз, Інк. |
Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
|
|
WO2014089324A1
(en)
|
2012-12-07 |
2014-06-12 |
Calitor Sciences, Llc |
Substituted cyclic compounds and methods of use
|
|
WO2014150000A1
(en)
|
2013-03-21 |
2014-09-25 |
Isp Investments Inc. |
Diacetylene film sensitized with photoinitiator and applications of the film
|
|
US9192609B2
(en)
|
2013-04-17 |
2015-11-24 |
Hedgepath Pharmaceuticals, Inc. |
Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
|
|
JP2016528252A
(ja)
*
|
2013-08-12 |
2016-09-15 |
トーカイ ファーマシューティカルズ， インコーポレイテッド |
アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
|
|
US9987275B2
(en)
|
2014-04-23 |
2018-06-05 |
The Brigham And Women's Hospital, Inc. |
Targeting PARP1 for treatment of TSC and cancers
|
|
US20150344968A1
(en)
|
2014-05-30 |
2015-12-03 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Methods for determining parp inhibitor and platinum resistance in cancer therapy
|
|
WO2016094391A1
(en)
|
2014-12-08 |
2016-06-16 |
Myriad Genetics, Inc. |
Methods and materials for predicting response to niraparib
|
|
WO2017023694A1
(en)
|
2015-08-03 |
2017-02-09 |
Pop Test Oncology Llc |
Pharmaceutical compositions and methods
|
|
RS66574B1
(sr)
|
2016-07-29 |
2025-03-31 |
Janssen Pharmaceutica Nv |
Niraparib za upotrebu u postupku lečenja raka prostate
|
|
US11040037B2
(en)
|
2016-10-04 |
2021-06-22 |
Pop Test Oncology Llc |
Therapeutic agents and methods
|
|
US11702443B2
(en)
|
2016-10-04 |
2023-07-18 |
Pop Test Oncology Llc |
Therapeutic agents and methods
|
|
JOP20190244A1
(ar)
|
2017-04-13 |
2019-10-13 |
Janssen Pharmaceutica Nv |
تركيبة علاجية لسرطان البروستاتا
|
|
US20190105332A1
(en)
|
2017-10-11 |
2019-04-11 |
Janssen Oncology, Inc. |
Methods of treating prostate cancer
|